Scientists develop nanobody inhibitors to target deadly Ebola virus

Ebola virus, one of the deadliest pathogens, has a fatality rate of about 50%, posing a serious threat to global health and safety. To address this challenge, researchers at the University of Minnesota and the Midwest Antiviral Drug Discovery (AViDD) Center have developed the first nanobody-based inhibitors targeting the Ebola virus.